Pharmacokinetics and biotransformation of biopharmaceuticals:by liquid chromatography with unit-mass and high-resolution mass spectrometric detection

Unlike the current situation for small-molecule drugs, the biotransformation of biopharmaceuticals is a largely unexplored field. Although much attention is paid to (the prevention of) degradation and structural alteration of protein-based drugs in pharmaceutical formulations, almost nothing is known about what happens to such a drug once it is dosed to a patient. An important reason for this is the fact that it is virtually impossible to investigate biotransformation using LBAs, because they typically cannot distinguish unchanged and biotransformed versions of the drug. With the increasing use of LC-MS/MS for protein quantification, it is now becoming more and more evident that in vivo chemical and enzymatic reactions of biopharmaceuticals are very common. Pharmacologically, biotransformation may affect the activity of a protein drug and, from an analytical perspective, it can also have a large influence on the concentration result that is reported.If we look at biopharmaceutical analysis from a more technical and instrumental point of view. So far, most protein LC-MS methods are being performed using triple-quadrupole mass spectrometry after sample digestion and further sample processing. This type of mass spectrometry has unit-mass resolution and its use for protein quantification essentially is an extension of the typical approach for small-molecule analysis. Very little is known about the quantitative possibilities of other high-resolution mass spectrometry (HRMS) approaches for biopharmaceuticals. HRMS is extensively used for qualitative purposes, such as the structural elucidation or confirmation of both small and large molecules, because of its high mass accuracy, but it also offers the option for quantitative analysis and extensive data re-processing. It can thus be used as an alternative detection technique for digested protein analysis with improved selectivity compared to unit-mass MS and it also is capable of quantifying intact proteins, which is virtually impossible on triple-quadrupole instrumentation

Intact protein bioanalysis by liquid chromatography - High-resolution mass spectrometry

This review discusses the challenges of quantitative protein bioanalysis by LC-MS at the protein level. We will notably address the possibilities and current limitations of protein sample preparation, separation by LC, the challenge of interpreting protein ESI-MS spectra and the options for protein quantification based on extracted ion chromatograms or deconvoluted spectra. The possibilities of high-resolution mass spectrometry (HRMS) with respect to improving the signal-to-noise (S/N) ratio and the challenges of analyzing complex mass spectra will be highlighted based on examples

Quantification of surfactant protein D (SPD) in human serum by liquid chromatography-mass spectrometry (LC-MS)

Quantification of intact proteins in complex biological matrices by liquid chromatography-mass spectrometry (LC-MS) is a promising analytical strategy but is technically challenging, notably for concentrations at or below the ng/mL level. Therefore, MS-based protein quantification is mostly based on measuring protein-specific peptides, so-called 'surrogate peptides', that are released through proteolysis. While quantitative protein bioanalysis based on peptide LC-MS is much more sensitive, not every peptide is suitable in this respect. For example, some peptides are too small to be unique for a protein while others are too large to be measured with sufficient sensitivity, so careful selection of appropriate peptides is essential. Here we present a validated LC-MS method for quantification of surfactant protein D (SPD) at clinically relevant levels between 5 and 500 ng/mL using 50 mu L. of serum. This method targets two SPD-specific peptides in the C-type lectin, ligand binding domain of the SPD protein. One of these peptides contains a methionine residue which would typically be avoided because of its unstable nature. Some quantitative methods do target methionine-containing peptides, and corresponding workflows feature an oxidation step at the peptide level using hydrogen peroxide (H2O2) to convert all methionine residues to more stable methionine sulfoxides. For our method, such a procedure was associated with peptide loss, hence we developed an oxidation procedure at the protein level using H2O2 to oxidize methionine residues and the enzyme catalase to quench excess H2O2. This procedure may be applicable to other quantitative methods based on a surrogate peptide-based approach and may potentially also be useful for MS-based workflows targeting intact proteins

Probable Mesozoic vicariance in the biogeography of Euphausiacea

The worldwide distribution of Euphausiacea is related to differences in character states found in the genera belonging to this order. An area cladogram is composed. The vicariant events postulated in this study made it possible to distinguish between different “hydroplates” of the “hydrotectonic (cf. Nelson, 1986) system” on the basis of general trends in distribution of these genera

Quantification of biopharmaceuticals and biomarkers in complex biological matrices: a comparison of liquid chromatography coupled to tandem mass spectrometry and ligand binding assays

The quantification of proteins (biopharmaceuticals or biomarkers) in complex biological samples such as blood plasma requires exquisite sensitivity and selectivity, as all biological matrices contain myriads of proteins that are all made of the same 20 proteinogenic amino acids, notwithstanding post-translational modifications. This review describes and compares the two main approaches, namely, ligand binding assays (LBAs) and liquid chromatography coupled to tandem mass spectrometry in the Selected Reaction Monitoring (SRM) mode. While LBAs remain the most widely used approach, SRM assays are gaining interest due to their generally better analytical performance (precision and accuracy) and their capacity for multiplex analyses. This article focuses on the possible reasons for the discrepancies between results obtained by LBAs and SRM assays

Separation of deamidated peptides with mixed-mode chromatography using phospholipid-functionalized monolithic stationary phases

Deamidation of asparagine (Asn) residues of monoclonal antibodies (mAbs) plays a pivotal role in the in vivo/vitro degradation or efficacy loss of biopharmaceuticals. However, a major challenge for MS analysis of deamidation of Asn-containing peptides in mAbs, is due to the fact that there is only a 1 Da mass shift between the native form (Asn residues) and deamidated forms (n-aspartyl (n-Asp) and isoaspartyl (isoAsp) residues with identical mass). Therefore, a chromatographic separation of the deamidated proteins and/or the peptides derived therefrom is needed prior to MS analysis. In this study, the monolithic column with various stationary phases, including reverse phase (RP), single phospholipid-functionalized and mixed phospholipid-functionalized monoliths, were prepared for the separation of the deamidation-sensitive signature peptide (IYPTNGYTR) of trastuzumab and its two deamidated products, n-Asp55 residue IYPTDGYTR and isoAsp55 residue IYPTisoDGYTR. Compared to the RP monolith, the phospholipid-functionalized monoliths provided mixed-mode interactions and exhibited better peak shape and separation selectivity. The effect of the parameters, including the type and concentration of buffer, temperature and pH value on the separation performance were investigated. Under the optimal conditions, the three peptides were fully separated on a mixed phosphocholine (PC) / phosphatidic acid (PA) functionalized monolith (poly (MDPC60PA40-co-EDMA)) due to the joint contribution of hydrophobic and electrostatic interactions. Therefore, the novel method based on the mixed phospholipids-functionalized monolithic column exhibited good potential for the analysis of deamidated peptides, which will be useful for the in-depth study of post-translational modifications of mAbs

Intact protein quantification in biological samples by liquid chromatography – high-resolution mass spectrometry: somatropin in rat plasma.

The quantitative determination of intact proteins in biological samples by LC with high-resolution MS detection can be a useful alternative to ligand-binding assays or LC-MS-based quantification of a surrogate peptide after protein digestion. The 22-kDa biopharmaceutical protein somatropin (recombinant human growth hormone) was quantified down to 10 ng/mL (0.45 nM) in 75 μL of rat plasma by the combination of an immunocapture step using an anti-somatropin antibody and LC-MS on a quadrupole-time of flight instrument. Accuracy and precision of the method as well as its selectivity and sensitivity did not depend on the width of the mass extraction window nor on whether only one or a summation of multiple charge states of the protein analyte were used as the detection response. Quantification based on deconvoluted mass spectra showed equally acceptable method performance but with a less favorable lower limit of quantification of 30 ng/mL. Concentrations in plasma after dosing of somatropin to rats correlated well for the deconvolution approach and the quantification based on the summation of the response of the four most intense charge states (14+ to 17+) of somatropin

LC-MS/MS-based monitoring of in vivo protein biotransformation:quantitative determination of trastuzumab and its deamidation products in human plasma

An LC-MS/MS-based method is described for quantitatively monitoring the in vivo deamidation of the biopharmaceutical monoclonal antibody trastuzumab at a crucial position in its complementarity determining region (CDR). The multiplexed LC-MS/MS assay using selected reaction monitoring (SRM) allows simultaneous quantitation of five molecular species derived from trastuzumab after tryptic digestion: a stable signature peptide (FTISADTSK), a deamidation-sensitive signature peptide (IYPTNGYTR), its deamidated products (IYPTDGYTR and IYPTisoDGYTR) and a succinimide intermediate (IYPTsuccGYTR). Digestion of a 50-μL plasma sample is performed at pH 7 for three hours at 37°C, which combines a reasonable (>80%) digestion efficiency with a minimal (<1%) formation of deamidation products during digestion. Rapid in vitro deamidation was observed at higher pH, leading to a (large) overestimation of the concentrations of deamidation products in the original plasma sample. The LC-MS/MS method was validated in accordance with international bioanalytical guidelines over the clinically relevant range of 0.5 to 500 µg/mL with bias and CV values well below 15%. Deamidation of trastuzumab was observed in plasma both in a 56-day in vitro forced degradation study (up to 37% of the total drug concentration) and in samples obtained from breast cancer patients after treatment with the drug for several months (up to 25%). Comparison with a validated ELISA method for trastuzumab showed that deamidation of the drug at the CDR leads to a loss of recognition by the antibodies used in the ELISA assay

Improving selectivity and sensitivity of protein quantitation by LC-HR-MS/MS: Determination of somatropin in rat plasma

AIM: Protein quantitation by digestion of a biological sample followed by LC-MS analysis of a signature peptide can be a challenge because of the high complexity of the digested matrix. Results/methodology: The use of LC with high-resolution (quadrupole-TOF) MS detection allowed quantitation of the 22-kDa biopharmaceutical somatropin in 60 μl of rat plasma down to 25 ng/ml with minimal further sample treatment. Reducing the mass extraction window to 0.01 Da considerably decreased the interference of tryptic peptides, enhanced sensitivity and improved accuracy and precision. Analysis with LC-MS/MS resulted in a less favorable limit of quantitation of 100 ng/ml. CONCLUSION: HRMS is an interesting option for the quantitation of proteins after digestion and has the potential to improve sensitivity with minimal method development